Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

被引：0
|
作者：
Manley, Paul W. [1 ]
Cowan-Jacob, Sandra W. [1 ]
Cozens, Robert [1 ]
Fendrich, Gabriele [1 ]
Jahnke, Wolfgang [1 ]
Roesel, Johannes L. [1 ]
Fabbro, Dorian [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1181 / 1181
页数：1
相关论文
共 50 条
  • [11] Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways
    Baer, Alan
    Colon-Moran, Winston
    Bhattarai, Nirjal
    SCIENTIFIC REPORTS, 2018, 8
  • [12] Oral fingolimod (FTY720) inhibits ongoing CNS autoimmunity and promotes recovery in mice with chronic experimental autoimmune encephalomyelitis
    Bernard, F.
    Sablone, M.
    Sansig, G.
    Rudin, S.
    Schubart, A.
    Cojean, C.
    Seabrook, T.
    Smith, P.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S58 - S58
  • [13] The prevalence of mutations in the ATP binding site of bcr-abl among patients with chronic myeloid leukemia.
    Bailey, TJ
    Neppalli, V
    Holman, CJ
    Dolan, M
    Brown, CA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (02) : 284 - 285
  • [14] Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis
    Chang Wook Lee
    Ji Woong Choi
    Jerold Chun
    Archives of Pharmacal Research, 2010, 33 : 1567 - 1574
  • [15] Neurological S1P Signaling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis
    Lee, Chang Wook
    Choi, Ji Woong
    Chun, Jerold
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (10) : 1567 - 1574
  • [16] FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model
    Gstalder, Cecile
    Ader, Isabelle
    Cuvillier, Olivier
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) : 2465 - 2474
  • [17] Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model
    Gao, Fei
    Liu, Yangfeng
    Li, Xiaowei
    Wang, Ying
    Wei, Dong
    Jiang, Wen
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 103 (02) : 187 - 196
  • [18] Bcr-Abl binding modes of dasatinib, imatinib and nilotinib: An NMR study.
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Fendrich, Gabriele
    Strauss, Andre
    Vapai, Navratna
    Grzesiek, Stephan
    Jahnke, Wolfgang
    BLOOD, 2006, 108 (11) : 224A - 224A
  • [19] Exploring the contribution of ubiquitin binding domain of Bcr-Abl in chronic myelogenous leukemia
    Chen, Ru
    Mahon, Gwen
    Tala, Ilona
    Chen, Qing
    Hu, Tinghui
    Li, Dan
    Ozer, Harvey
    Whitehead, Ian
    CANCER RESEARCH, 2012, 72
  • [20] FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling
    Zhaoyang Lu
    Jiabei Wang
    Tongsen Zheng
    Yingjian Liang
    Dalong Yin
    Ruipeng Song
    Tiemin Pei
    Shangha Pan
    Hongchi Jiang
    Lianxin Liu
    BMC Cancer, 14
12345